Neela Biotech Raises £2.1M ($2.8M) Funding to Turn Waste Into Jet Fuel With AI

Neela Biotech, the Cambridge-based synthetic biology startup, has raised £2.1 million ($2.8 million) in pre-seed funding led by Elbow Beach Capital, with participation from Ascension, Cambridge Enterprise, Ventures Together, and strategic angel investors . The round follows grant funding from Innovate UK and the Henry Royce Institute, bringing total disclosed support to over £2.5 million ($3.3 million).

The funding comes as Neela Biotech advances its Controlled Microbial Upcycling (CMU) process – an AI-guided microbial method that converts food, agricultural, and forestry waste into fatty acids that can be processed into sustainable aviation fuel (SAF) using existing refinery infrastructure . The company aims to reach pilot-scale trials with the new capital, addressing a critical feedstock bottleneck that limits the SAF industry today .

Neela Biotech Funding Overview By CREDX Media

Startup Name	Neela Biotech
Founders	Dr. Deepanshu Singh (CEO), Friederike Nintzel (CTO)
Founded	2025
HQ	Cambridge, UK
Round	Pre-Seed Funding
Amount Raised	£2.1M ($2.8M)
Valuation	Not disclosed
Category	Climate Tech, Synthetic Biology, Sustainable Aviation Fuel
Lead Investor	Elbow Beach Capital
Key Investors	Ascension, Cambridge Enterprise, Ventures Together
Grant Support	Innovate UK, Henry Royce Institute
Total Funding Raised	~£2.5M+ ($3.3M)
Key Process	Controlled Microbial Upcycling (CMU)
Target Market	$391 billion global jet fuel market

💡 Use of Funds

• Pilot-Scale Development: Advancing the CMU process toward pilot-scale trials.
• SAF Feedstock Expansion: Producing alternative HEFA-compatible feedstocks from diverse waste streams.
• Team Growth: Hiring technical talent including a founding chemical engineer.

Startup Overview: Neela Biotech

What Neela Biotech Is Building in Simple Words

Neela Biotech has developed a process that uses AI and synthetic biology to turn waste into the precursors for jet fuel. Rather than competing with food crops for land, the company’s Controlled Microbial Upcycling (CMU) process converts food waste, agricultural residues, and forestry byproducts into fatty acids—the same feedstocks used in the most commercially mature SAF pathway, HEFA (Hydroprocessed Esters and Fatty Acids) .

• Feedstock-Agnostic: Works with diverse waste streams instead of relying on limited waste oils and fats.
• Leverages Existing Infrastructure: Designed to operate within existing biogas and refinery facilities, reducing capital costs.
• AI-Guided Process Design: Uses machine learning to optimize microbial bioprocesses for efficiency and yield.
• Targets the HEFA Bottleneck: Produces alternative HEFA-compatible feedstocks to address the waste oil supply constraint that limits SAF scaling .
• Carbon-Negative Potential: The process is designed to produce carbon-negative fuels by diverting waste from decomposition and avoiding fossil fuel extraction.

Why Neela Biotech Matters

1. SAF Is Stuck at Less Than 1% of Jet Fuel Aviation is one of the hardest sectors to decarbonize. SAFs offer a drop-in solution, but they currently account for less than 1% of global jet fuel usage . The industry needs scalable, cost-effective pathways to reach net zero targets.
2. HEFA Feedstock Is the Bottleneck The HEFA pathway—the most commercially mature SAF production method—relies on waste oils and fats. But there are not enough waste oils to scale HEFA beyond a small fraction of global jet fuel demand, even by 2050 . Neela Biotech directly addresses this constraint by creating HEFA-compatible feedstocks from abundant waste streams.
3. Existing Infrastructure Reduces Scale-Up Risk Unlike approaches that require entirely new production facilities, Neela’s CMU process builds on proven biogas technology. This allows the company to leverage existing infrastructure, reduce capital costs, and scale faster than alternative approaches .
4. Demand Is Rising Rapidly Airlines’ net zero commitments and global SAF mandates are driving unprecedented demand for sustainable aviation fuel. The global jet fuel market is valued at $391 billion, and SAF mandates are increasing globally .

Startup Story: From Cambridge Labs to the SAF Feedstock Race

Neela Biotech was founded by two early-career researchers who met at the University of Cambridge through a shared passion for sustainability and climate tech . Dr. Deepanshu Singh, a researcher in sustainable aviation and Business Development Lead at the Aviation Impact Accelerator (AIA) at the Whittle Laboratory, brought deep knowledge of aviation’s decarbonization challenge. Friederike Nintzel, a Marie Curie PhD fellow in synthetic biology, contributed expertise in microbiome engineering and AI-driven bioprocess design .

The founding insight came from recognizing a fundamental inefficiency in current SAF pathways. As the founders wrote, most pathways “break down complex feedstocks into simple molecules, the so-called ‘syngas’, only to rebuild them back into complex hydrocarbons, the jet fuel. This is an extremely energy- and cost-inefficient route” .

Their solution—Controlled Microbial Upcycling—bypasses these energy-intensive steps by using microbial action to convert waste directly into fatty acids. The approach became feasible only recently due to advances in microbiome engineering and AI-driven bioprocess design .

The company has moved quickly since incorporating in early 2025. It won first prize at the 2025 Cambridge Zero Climate Challenge, was selected for the IAG Innovation Accelerator (IAG is the parent company of British Airways, Aer Lingus, Iberia, and Vueling), and secured grant funding from the Henry Royce Institute for a feasibility study with the Aviation Impact Accelerator . The pre-seed round now provides capital to reach pilot-scale development .

Our Take on Neela Biotech

Neela Biotech is solving one of the most concrete bottlenecks in aviation decarbonization—feedstock supply for HEFA SAF—and doing it with a capital-efficient model that leverages existing infrastructure.

The SAF industry has a scaling problem. HEFA is the most mature pathway, but it depends on waste oils and fats that are fundamentally limited in supply. Other pathways exist, but they require new production facilities, higher capital costs, and longer timelines. Neela’s insight is that the fastest route to scaling SAF is not inventing a new pathway, but producing more feedstock for the pathway that already works.

The £2.1 million ($2.8 million) pre-seed is justified on multiple fronts: a clear technical thesis addressing a documented industry bottleneck, strong early validation (Cambridge Zero Climate Challenge win, IAG Accelerator, Innovate UK and Henry Royce grants), and a founding team with complementary expertise in aviation and synthetic biology .

The real risk is scale-up uncertainty. The company is moving toward pilot-scale trials, but has not yet demonstrated commercial-scale production. As one analysis noted, “the £2.1 million round provides capital to reach pilot-scale development, but it should not yet be interpreted as evidence of commercial-scale SAF production” . The path from pilot to commercial plant involves technical, regulatory, and financing hurdles that many climate tech startups fail to clear.

For now, Neela Biotech has capital, grants, accelerator support, and a clear technical thesis. The next 18 months will determine whether CMU can deliver at pilot scale.

Founder Background: The Aviation Researcher and the Synthetic Biologist

Dr. Deepanshu Singh (CEO) brings an unusual combination of aviation expertise and climate tech focus. As a researcher in sustainable aviation and Business Development Lead at the Aviation Impact Accelerator at Cambridge’s Whittle Laboratory, he understands the industry’s decarbonization constraints from both technical and commercial perspectives. His framing of the problem: “Aviation is the most emissions-intensive mode of transport. SAFs offer a drop-in solution to decarbonise the sector, yet they make up less than 1% jet fuel usage today” .

Friederike Nintzel (CTO) is a final-year Marie Curie PhD fellow in synthetic biology at Cambridge. Her expertise in microbiome engineering and AI-driven bioprocess design is directly relevant to Neela’s CMU process. Her thesis on timing: “Our approach has only recently become feasible due to advances in microbiome engineering and AI-driven bio-process design” .

The combination—Singh’s aviation industry knowledge and Nintzel’s synthetic biology depth—positions Neela to navigate both the technical and commercial challenges of SAF production.

The SAF Feedstock Race Nobody Expected

Neela Biotech operates in a growing field of startups and established players working on sustainable aviation fuel.

The SAF market is projected to grow dramatically as mandates take effect. The UK has introduced a SAF mandate requiring at least 10% of jet fuel to be sustainable by 2030. The EU has similar targets. Airlines including IAG have committed to significant SAF usage .

Most SAF today is produced via the HEFA pathway using waste oils and fats. The fundamental constraint is feedstock availability. Neela’s differentiation is its focus on creating more HEFA-compatible feedstock from abundant waste streams, rather than developing an entirely new SAF pathway that would require new infrastructure and certification .

The competitive moat, if it materializes, would be the CMU process itself—an AI-optimized microbial method for converting diverse waste into fatty acids. If the process works at scale, it opens up a feedstock supply that is not limited by waste oil availability.

Founder Intelligence: What Founders Can Learn from Neela Biotech

• Solve the bottleneck, not the whole problem: Neela didn’t try to invent a new SAF pathway—it focused on the feedstock constraint that limits the existing pathway. Identifying the real bottleneck is often more valuable than building something new.
• Leverage existing infrastructure: By building on biogas technology, Neela reduces capital costs and scale-up risk. This is a recurring theme in successful climate tech companies.
• Validate commercially before scaling: The IAG Innovation Accelerator provided direct access to airlines, fuel supply chains, and certification expertise. This kind of customer validation is as important as technical validation.
• Grants are non-dilutive validation: Innovate UK and Henry Royce Institute grants provided both capital and external validation of the technology thesis.

Investor Intelligence: Why This Round Gets Premium Capital

Elbow Beach Capital led the round. CEO Jonathan Pollock framed the thesis: the investment “reflected the need for SAF technologies that address both fuel availability and production economics”.

Cambridge Enterprise participated—the commercialization arm of the University of Cambridge, which supports spinouts from university research. Ascension and Ventures Together brought additional early-stage expertise.

The grant support from Innovate UK (under the Fast Track program) and the Henry Royce Institute provides non-dilutive capital and institutional validation.

The Road Ahead for Neela Biotech

Expansion Targets

With £2.1 million ($2.8 million) in capital, Neela Biotech will:

• Advance the CMU process toward pilot-scale trials
• Produce alternative HEFA-compatible feedstocks from diverse waste streams
• Hire technical talent including a founding chemical engineer
• Continue collaboration with the Aviation Impact Accelerator on technoeconomic and lifecycle assessments

Competitive Response

Expect:

• Other SAF feedstock startups to emerge targeting the HEFA bottleneck
• Traditional SAF producers to explore feedstock diversification
• Biotechnology companies to apply similar microbial upcycling approaches
• Neela’s moat: CMU process IP + AI-driven bioprocess design + existing infrastructure leverage

Conclusion

Neela Biotech’s £2.1 million ($2.8 million) pre-seed funding validates the thesis that scaling SAF requires solving the feedstock bottleneck, not just inventing new pathways. The company’s CMU process—converting waste into HEFA-compatible fatty acids—addresses a documented constraint in the most commercially mature SAF pathway.

Market tailwinds favor Neela: rising SAF mandates, airline net zero commitments, and the fundamental limitation of waste oil supply. The company’s existing infrastructure leverage, AI-driven process design, and IAG accelerator support position it to pursue pilot-scale development.

For deep analysis of climate tech funding, synthetic biology innovation, and companies reshaping sustainable aviation, explore CREDX Media for comprehensive coverage of startup funding trends, valuation intelligence, and founder playbooks.

Want the latest funding news and market insights delivered straight to your inbox? Subscribe to CredX Letters for verified deal terms, valuation benchmarks, and daily macro signals.

Frequently Asked Questions

1. What is Neela Biotech’s total funding and latest round size?
Neela Biotech has raised approximately £2.5 million+ ($3.3 million) in total disclosed support. Its £2.1 million ($2.8 million) pre-seed round was led by Elbow Beach Capital in October 2026, following grants from Innovate UK and the Henry Royce Institute .

2. How much did Neela Biotech raise in its pre-seed round and who led the investment?
Neela Biotech raised £2.1 million ($2.8 million) in pre-seed funding led by Elbow Beach Capital, with participation from Ascension, Cambridge Enterprise, Ventures Together, and strategic angels .

3. What is the valuation of Neela Biotech?
Neela Biotech did not disclose its post-money valuation in the pre-seed round. The company was founded in 2025 and is at an early stage of development .

4. Who are the major investors in Neela Biotech?
Major investors include Elbow Beach Capital (pre-seed lead), Ascension, Cambridge Enterprise, and Ventures Together. Innovate UK and the Henry Royce Institute provided grant funding .

5. Who are Neela Biotech’s founders?
Neela Biotech was founded in 2025 by Dr. Deepanshu Singh (CEO) and Friederike Nintzel (CTO). Singh is a researcher in sustainable aviation at the Aviation Impact Accelerator; Nintzel is a Marie Curie PhD fellow in synthetic biology .

6. What is Neela Biotech’s Controlled Microbial Upcycling (CMU) process?
CMU is an AI-guided microbial process that converts food, agricultural, and forestry waste into fatty acids that can be used as precursors for HEFA sustainable aviation fuel, leveraging existing biogas and refinery infrastructure .

7. What problem does Neela Biotech solve for the SAF industry?
Neela Biotech addresses the feedstock bottleneck that limits HEFA-based SAF production. Waste oils and fats are fundamentally limited in supply; CMU produces alternative HEFA-compatible feedstocks from abundant waste streams .

8. How does Neela Biotech’s approach differ from other SAF pathways?
Unlike pathways that require new production facilities or compete with food production, Neela’s CMU process leverages existing biogas infrastructure and uses waste feedstocks that do not compete for food, land, or water .

9. What are Neela Biotech’s plans for the £2.1 million pre-seed capital?
Neela Biotech will use the funding to move its CMU technology toward pilot-scale trials, producing alternative HEFA-compatible feedstocks and hiring technical talent .

10. What recognition has Neela Biotech received?
Neela Biotech won the 2025 Cambridge Zero Climate Challenge, is part of the IAG Innovation Accelerator, and was selected for the King’s E-Lab SPARK incubator. It also received grants from Innovate UK and the Henry Royce Institute .

11. Who is the CEO of Neela Biotech?
Dr. Deepanshu Singh serves as CEO and co-founder of Neela Biotech. He is a researcher in sustainable aviation and Business Development Lead at the Aviation Impact Accelerator at the University of Cambridge .